What's breaking now, across thousands of outlets.
The fledgling startup has $90 million to develop a pipeline of drugs, led by a Charcot-Marie-Tooth disease medicine, that Actio was working on when Jazz Pharmaeuticals bought its lead epilepsy program.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
To end polio, we must reach the children still being missed newspress_en Fri, 10/30/2026 - 10:29 Opinion Most families who come to Mirwais Hospital in Afghanistan’s southern Kandahar province arrive…
Indian drug regulators ordered Sun Pharma to halt eye-care drug production at its Assam plant over quality lapses, following the recall of 332 batches of ophthalmic products.
Scientists have uncovered hidden aggressive cancer cells in children whose tumors were previously considered lower risk, revealing why some cases of rhabdomyosarcoma become unexpectedly deadly.
In Germany new recommendations for coronavirus vaccinations now apply. Even last year far fewer people had themselves vaccinated against flu.
After shipping its precision epilepsy drug to Jazz Pharmaceuticals, Actio Biosciences has spun out the remainder of its genetics-driven pipeline into a new company called Setara Biosciences.
A patient has undergone stem-cell therapy for Parkinson's disease, a chronic, degenerative neurological disorder that affects the body's motor system, often causing shaking and other difficulties with…
